A new report by Wells Fargo spotlights how GLP-1 weight loss drugs are reshaping the healthcare industry by addressing obesity.

Wells Fargo released a report Thursday which notes that much of the American healthcare system has been structured around obesity, given it has become a foundational condition in the country with 40.3% of adults considered obese and 9.4% severely obese.

Usage of GLP-1 drugs surged in recent years, rising over 140% from 2022 to 2024, which had a significant impact on hospital services aimed at treating obesity. In that same timeframe, bariatric surgery volumes fell 34.1%.

MAJOR PBMS TO BOOST PRESCRIPTION DRUG PRICE…

Read the full article at FOXBUSINESS.COM